Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEOGlobeNewsWire • 03/22/23
Tiziana Life Sciences receives positive coverage on foralumab in Forbes articleProactive Investors • 03/17/23
Tiziana Life Sciences hails publication in science journal of article on mechanism of action for intranasal foralumabProactive Investors • 03/08/23
Tiziana Life Sciences Announces Publication in Proceedings of the National Academy of Sciences (PNAS) Illustrating the Immunological Basis of the Mechanism of Action for Intranasal ForalumabGlobeNewsWire • 03/08/23
Tiziana Life Sciences says IND filed for Phase 2 study of milciclib in combination with gemcitabine for non-small cell lung cancerProactive Investors • 01/04/23
Tiziana Life Sciences Announces IND filed for Phase 2 Study of Milciclib in Combination with Gemcitabine for Non-Small Cell Lung CancerGlobeNewsWire • 01/04/23
Tiziana Life Sciences hails more improvements in MS patient after 11 months dosing with intranasal foralumabProactive Investors • 01/03/23
Tiziana Life Sciences Announces Additional Clinical Improvements in the Second Patient with Non-Active Secondary Progressive Multiple Sclerosis (SPMS) After Eleven Months of Dosing with Intranasal ForalumabGlobeNewsWire • 01/03/23
Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) - Updated Interim Results for the Six Months Ended 30 June 2022GlobeNewsWire • 12/29/22
Tiziana Life Sciences ups R&D spend in first half of 2022 as it advances its next-generation therapeuticsProactive Investors • 12/28/22
Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) - Interim Results for the Six Months Ended 30 June 2022GlobeNewsWire • 12/27/22
Tiziana Life Sciences reveals successful completion of intranasal foralumab pre-clinical safety studyProactive Investors • 12/15/22
Tiziana Life Sciences Announces Completion of Prerequisite Pre-Clinical Safety StudyGlobeNewsWire • 12/15/22
Tiziana Life Sciences Ltd. Granted 180-day Extension by Nasdaq to Meet Minimum Bid Price RequirementsGlobeNewsWire • 12/14/22
Tiziana Life Sciences publishes peer-reviewed research, showing intranasal administered drug for autoimmune diseases is safe in humansProactive Investors • 11/23/22
Tiziana Announces Publication of a Peer-Reviewed Article on the Intranasal Administration of Foralumab Demonstrating Modulated Effector CD8+ T cell Function and an Induced T Cell Regulatory Response in Human SubjectsGlobeNewsWire • 11/23/22
Tiziana Life Sciences Announces Near-Term Strategic Focus on Intranasal Foralumab for Diseases of the Central Nervous System (CNS)GlobeNewsWire • 11/10/22
Tiziana Life Sciences Announces Purchase of Common Shares by Executive ChairmanGlobeNewsWire • 11/03/22
Tiziana Life Sciences Completes Enrollment of the First Patient Cohort for its Intermediate-Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis PatientsGlobeNewsWire • 11/02/22
Tiziana Life Sciences starts enrollment of first patient cohort in program to evaluate foralumab in non-active Secondary Progressive Multiple Sclerosis patientsProactive Investors • 10/26/22